secwatch.observer — SEC 8-K summary
======================================

Issuer:     Instil Bio, Inc. (TIL)
CIK:        0001789769
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001789769-23-000083
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Instil Bio Q2 2023 net loss $18.7M; cash $202.9M, ITIL-306 trial start 2H 2023
------------------------------------------------------------------------------

- Net loss of $18.7M ($0.14/share) vs. $59.0M loss in Q2 2022; R&D expenses down to $8.5M from $41.5M.
- Cash, equivalents, restricted cash and marketable securities $202.9M as of June 30, 2023; cash runway expected beyond 2026.
- ITIL-306 (CoStAR-TIL) clinical trial ITIL-306-202 anticipated to start in 2H 2023; initial data expected in 2024.
- Manufacturing process improvements doubled CoStAR-TIL yield in final product from verification runs.
- Restructuring and impairment charges of $1.0M in Q2 and $25.6M for six months ended June 30, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789769/000178976923000083/0001789769-23-000083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789769/000178976923000083/til-20230814.htm
  HTML page:      https://secwatch.observer/filing/0001789769-23-000083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer